Report cover image

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 184 Pages
SKU # IRE18437789

Description

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030


The Cystic Fibrosis Market size was estimated at USD 5.88 billion in 2023 and expected to reach USD 6.44 billion in 2024, at a CAGR 9.53% to reach USD 11.13 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cystic Fibrosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cystic Fibrosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage


This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Bronchodilators
CFTR Modulators
Mucolytics
Pancreatic Enzyme Supplements
Route of Administration
Inhaled Drugs
Oral Drugs
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cystic Fibrosis Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cystic Fibrosis Market?
3. What are the technology trends and regulatory frameworks in the Cystic Fibrosis Market?
4. What is the market share of the leading vendors in the Cystic Fibrosis Market?
5. Which modes and strategic moves are suitable for entering the Cystic Fibrosis Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

184 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cystic Fibrosis Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
5.1.1.2. Increasing global awareness for Cystic Fibrosis
5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies
5.1.2. Restraints
5.1.2.1. Expiring patents and generic drugs
5.1.2.2. Increase in genetic mutation rate
5.1.3. Opportunities
5.1.3.1. Research & development activities and robust drug development pipeline
5.1.3.2. Growing strategic collaborations, merger, and acquisition
5.1.4. Challenges
5.1.4.1. High cost involved in treatment and complicated pathophysiology
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cystic Fibrosis Market, by Drug Class
6.1. Introduction
6.2. Bronchodilators
6.3. CFTR Modulators
6.4. Mucolytics
6.5. Pancreatic Enzyme Supplements
7. Cystic Fibrosis Market, by Route of Administration
7.1. Introduction
7.2. Inhaled Drugs
7.3. Oral Drugs
8. Americas Cystic Fibrosis Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cystic Fibrosis Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cystic Fibrosis Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Alcresta Therapeutics, Inc.
12.1.3. AlgiPharma AS
12.1.4. AstraZeneca PLC
12.1.5. CHIESI Farmaceutici S.p.A.
12.1.6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Galapagos NV
12.1.9. Gilead Sciences, Inc.
12.1.10. Johnson & Johnson Services, Inc.
12.1.11. NovaBiotics Ltd.
12.1.12. Novartis AG
12.1.13. Pharmaxis Ltd.
12.1.14. PTC Therapeutics, Inc.
12.1.15. Vertex Pharmaceuticals Incorporated
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030
FIGURE 3. CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CYSTIC FIBROSIS MARKET DYNAMICS
FIGURE 7. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us